Updated just now · Live
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. Its key products include Humira, Skyrizi, Rinvoq, and Botox, spanning immunology, oncology, aesthetics, neuroscience, and eye care therapeutic areas.
AbbVie Inc. operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for ABBV.
How to read insider trading filings
Johnson & Johnson
UnitedHealth Group Incorporated
Merck & Co., Inc.
Eli Lilly and Company
Thermo Fisher Scientific Inc.
Abbott Laboratories
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). ABBV Stock Intelligence Report. [stoxpulse.com/stocks/abbv]
Disclaimer: The information on this page about AbbVie Inc. (ABBV) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for AbbVie Inc..
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No earnings data available.
Canaccord Calls AbbVie a Core Holding With a $262 ...
4h ago
Novartis: Buy Thesis Fades Into Q1 2026 Results (R...
6h ago
StoxPulse AI results for ABBV: Pulse Score 54/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$360.31B
P/E Ratio
96.8
EPS
$1.02
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. Its key products include Humira, Skyrizi, Rinvoq, and Botox, spanning immunology, oncology, aesthetics, neuroscience, and eye care therapeutic areas.
Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?
Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade)
Correction to AbbVie Article on April 20
Jim Cramer's top 10 things to watch in the stock market Tuesday
Here's Why AbbVie (ABBV) Fell More Than Broader Market
Trump Signed a Psychedelic Drugs Order—and These 4 Stocks Surged
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada
AbbVie Sponsors New BioLabs Facility in Toronto